ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bracco and Sichuan Biokin Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BraccoSichuan Biokin Pharmaceutical
studies on the registry66146
open to participants now5100
phase 3 studies under way136
reach primary completion within a year050
programswith a study of their own in two years319

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBraccoSichuan Biokin Pharmaceutical
Phase 100%

Sichuan Biokin Pharmaceutical: 8 of its 19 programs at phase 1

  1. SI-B036phase 1
  2. BL-M24D1phase 1
  3. GNC-077phase 1
  4. Antibody-drug Conjugate BL-M17D1phase 1
  5. BL-ARC002phase 1

and 3 more — sign in to see them all

42%
Phase 2

Bracco: 2 of its 3 programs at phase 2

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2
67%

Sichuan Biokin Pharmaceutical: 4 of its 19 programs at phase 2

  1. BL-M08D1phase 2
  2. emfizatamabphase 2
  3. BL-M09D1phase 2
  4. glecirasibphase 2
21%
Phase 300%

Sichuan Biokin Pharmaceutical: 7 of its 19 programs at phase 3

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3
  4. Anti-DLL3 Antibody-drug Conjugate BL-M14D1phase 3
  5. Cytarabinephase 3

and 2 more — sign in to see them all

37%
Approved, new studies

Bracco: 1 of its 3 programs at approved, new studies

  1. fluciclovine F-18approved, new study
33%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bracco0 readouts · 0 phase 3············
Sichuan Biokin Pharmaceutical8 readouts · 1 phase 3

Sichuan Biokin Pharmaceutical, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. izalontamab brengitecanphase 3 · Nov 0 · NCT06118333

Sichuan Biokin Pharmaceutical, Dec ’26: 4 programs whose next study reaches primary completion

  1. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3 · Dec 0 · NCT05924750
  2. BL-M08D1phase 2 · Dec 0 · NCT06718621
  3. emfizatamabphase 2 · Dec 0 · NCT05623982
  4. trastuzumab brengitecanphase 3 · Dec 0 · NCT06114511
·

Sichuan Biokin Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1phase 1 · Feb 28 · NCT07021066
··

Sichuan Biokin Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. BL-M09D1phase 2 · May 0 · NCT06954077

Sichuan Biokin Pharmaceutical, Jun ’27: 1 program whose next study reaches primary completion

  1. GNC-077phase 1 · Jun 0 · NCT06755242
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bracco

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Sichuan Biokin Pharmaceutical

New programs 2

  • SI-B037phase 1 · first study · Nov 10
  • glecirasibphase 2 · first study · Sep 14 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionBraccoSichuan Biokin Pharmaceutical
Breast Neoplasmsboth · compare here

Bracco in Breast Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Breast Neoplasms in search

Sichuan Biokin Pharmaceutical in Breast Neoplasms: 6 programs

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. SI-B036phase 1
  4. GNC-077phase 1
  5. Antibody-drug Conjugate BL-M17D1phase 1

and 1 more — sign in to see them all

Their studies: Sichuan Biokin Pharmaceutical’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Bracco in Colorectal Neoplasms: 2 programs

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2

Their studies: Bracco’s studies of Colorectal Neoplasms in search

Sichuan Biokin Pharmaceutical in Colorectal Neoplasms: 1 program

  1. trastuzumab brengitecanphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Colorectal Neoplasms in search

Prostatic Neoplasmsboth · compare here

Bracco in Prostatic Neoplasms: 2 programs

  1. Gallium-68phase 2
  2. fluciclovine F-18approved, new study

Their studies: Bracco’s studies of Prostatic Neoplasms in search

Sichuan Biokin Pharmaceutical in Prostatic Neoplasms: 1 program

  1. Lutetium-177phase 1

Their studies: Sichuan Biokin Pharmaceutical’s studies of Prostatic Neoplasms in search

Urinary Bladder Neoplasmsboth · compare here

Bracco in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Urinary Bladder Neoplasms in search

Sichuan Biokin Pharmaceutical in Urinary Bladder Neoplasms: 1 program

  1. trastuzumab brengitecanphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Urinary Bladder Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Bracco 2 of 3 · Sichuan Biokin Pharmaceutical 9 of 19 programs (3 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.